Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will support AGEN1181 (botensilimab) and AGEN2034 (balstilimab) clinical development, including its planned Phase 3 in its lead indication of patients with metastatic, relapsed/refractory colorectal cancer or dMMR, who are without active liver metastases.
Lead Product(s): Botensilimab,Balstilimab
Therapeutic Area: Oncology Product Name: AGEN1181
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Agenus
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 07, 2024
Details:
Zelsuvmi (berdazimer topical gel, 10.3%) is a nitric oxide (NO) releasing agent which is approved for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Zelsuvmi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The partnership aims to accelerate Phase 3 development of Qtorin™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
Lead Product(s): Sirolimus
Therapeutic Area: Rare Diseases and Disorders Product Name: Qtorin
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Palvella Therapeutics
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Partnership December 01, 2023
Details:
Through the acquisition, Ligand acquires royalty on Sanofi’s Tzield (teplizumab-mzwv), the first disease-modifying therapy in type 1 diabetes and a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and children aged 8 years and older with Stage 2 T1D.
Lead Product(s): Teplizumab-mzwv
Therapeutic Area: Endocrinology Product Name: Tzield
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Tolerance Therapeutics
Deal Size: $20.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition November 01, 2023
Details:
Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of TAK-935 (soticlestat), being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ovid Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 18, 2023
Details:
Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novan
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Divestment September 27, 2023
Details:
Filspari (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with IgAN. It is being investigated for focal segmental glomerulosclerosis.
Lead Product(s): Sparsentan
Therapeutic Area: Nephrology Product Name: Filspari
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Travere Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.
Lead Product(s): 21-Valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: V116
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novan
Deal Size: $15.0 million Upfront Cash: $15.0 million
Deal Type: Acquisition July 17, 2023
Details:
SB206 (berdazimer sodium), the active ingredient in berdazimer gel, 10.3% (SB206), is a new chemical entity, for the treatment of molluscum contagiosum is a potential first-in-class topical nitric oxide-releasing agent with positive Phase 3 data submitted to the FDA.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023